Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDC-501 (Lenalidomide) Dose Regimens in Relapsed/Refractory Multiple Myeloma
NCT00044018Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2002
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by Celgene Corporation. Started Apr 2002; status: completed.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00044018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044018.